English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Celgene Corporation to Enter into a Strategic Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers

Jul. 5, 2017

Celgene Corp. and BeiGene entered into a strategic collaboration to develop and commercialize BeiGene's investigational PD-1 inhibitor, BGB-A317, for patients with solid tumor cancers global markets outside of Asia. BeiGene will acquire Celgene's commercial operations in China and gain an exclusive license to commercialize Celgene's approved therapies in China - ABRAXANE®, REVLIMID® and VIDAZA®.